
BTSG Stock Forecast & Price Target
BTSG Analyst Ratings
Bulls say
BrightSpring Health Services Inc. has demonstrated impressive growth in its OP Rehab segment, achieving growth in the double-digit percentage range while generating attractive margins. The Pharmacy Solutions segment notably reported a substantial increase in specialty revenue, projected at approximately $2.6 billion for 2025, reflecting a year-over-year growth of 43%, alongside a promising EBITDA margin increase. Additionally, management expresses confidence in enhancing margins and EBITDA through strategic acquisitions, while the Provider Services division benefits from stable reimbursement trends and a notable 15% year-over-year increase in home health average daily census in 4Q:25.
Bears say
BrightSpring Health Services Inc. faces potential revenue challenges due to the vulnerability of its clients and their budget priorities, which may weaken its business performance. Additionally, concerns regarding reduced prescription writing and drug utilization by healthcare professionals could adversely impact the company's revenues, operating results, and cash flows. The company's significant debt load further constrains its ability to invest in growth, potentially limiting expansion opportunities in an increasingly competitive market.
This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.
BTSG Analyst Forecast & Price Prediction
Start investing in BTSG
Order type
Buy in
Order amount
Est. shares
0 shares